This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Autologous Stem Cell Rescue for Primary Amyloidosis

This study has been completed.
Information provided by:
Stanford University Identifier:
First received: September 13, 2005
Last updated: September 10, 2010
Last verified: September 2010
To evaluate the role of high dose therapy and autologous hematopoietic cell transplant for amyloidosis.

Condition Intervention Phase
Amyloidosis Blood and Marrow Transplant (BMT) Procedure: high dose chemo then auto hematopoietic cell transplant Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: High Dose Chemotherapy and Autologous Stem Cell Rescue for Primary Amyloidosis

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • To evaluate the role of high dose therapy and autologous hematopoietic cell transplant for amyloidosis

Estimated Enrollment: 50
Study Start Date: April 1998
Study Completion Date: February 2010
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Detailed Description:
To learn about the use of high dose chemotherapy followed by transplantation using peripheral blood stem cells.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:1. Primary amyloidosis

2. Age < 75 years.

3. Patients must have their pathology reviewed and the diagnosis confirmed at Stanford University Medical Center.

4. Patients who have undergone bone marrow transplantation previously will not be eligible.

5. Patients must have a Karnofsky performance status greater than 70%.

6. Patients must have a serum creatinine less than 2 mg/dl or creatinine clearance greater than 30 ml/min, bilirubin less than 2 mg/dl, transaminases less than two times normal, left ventricular ejection fraction >45% on echocardiography, cardiac index > 1.8 liters/min/m^2 and pulmonary function tests demonstrating FEV1 and DLCO > 60%.

7. Patients must be HIV negative.

8. Pregnant or lactating women will not be eligible to participate.

9. Patients must provide signed informed consent.

10. Patients with multiple myeloma and amyloid are eligible.

Exclusion Criteria:1. prior blood or marrow transplant

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00186407

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Principal Investigator: Sally Arai Stanford University
  More Information

Responsible Party: Sally Arai, Stanford University School of Medicine Identifier: NCT00186407     History of Changes
Other Study ID Numbers: BMT92
Study First Received: September 13, 2005
Last Updated: September 10, 2010

Additional relevant MeSH terms:
Proteostasis Deficiencies
Metabolic Diseases processed this record on August 18, 2017